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Abstract
Background: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through
testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans.
Methods: Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms
(DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-
based engineering tool.
Results: Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than
10 % for most criteria; however, a deviation unacceptable rate of more than 20 % was computed for the planning
target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the
IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters
in which PSPT plans resulted in lower values than IMRT plans were: lung V5Gy (%) (34.4 in PSPT and 47.2 in IMRT);
maximum spinal cord dose (31.7 Gy in PSPT and 43.5 Gy in IMRT); heart V5Gy (%) (19 in PSPT and 47 in IMRT); heart
V30Gy (%) (11 in PSPT and 19 in IMRT); heart V45Gy (%) (7.8 in PSPT and 12.1 in IMRT); heart V50% (Gy) (7.1 in PSPT and
9.8 in IMRT) and mean heart dose (7.7 Gy in PSPT and 14.9 Gy in IMRT).
Conclusions: The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable.
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Introduction
Lung cancer is the main cause of cancer death in the
United States (US) [1, 2]. In the year 2015, a total of
221,200 new cases and 158,040 deaths from lung cancer
are estimated in the US [3]. Non-small cell lung cancer
(NSCLC) accounts for about 80–85 % of these cases [1–3]
and approximately 30 % of them are considered to be lo-
cally advanced, comprising both stage IIIA and IIIB in the
current American Joint Committee on Cancer (AJCC) sta-
ging system [1]. Radiation therapy plus chemotherapy is the
accepted standard of care for patients with locally advanced
NSCLC. Proton therapy generally allows for reduced doses
to organs at risk compared with photon therapy due to the
physical properties of the proton beam, with essentially no
dose delivered distal to the characteristic Bragg Peak [4, 5].
RTOG 1308 is a phase III randomized trial comparing
overall survival after photon versus proton chemoradiother-
apy for inoperable stage II-IIIB NSCLC. The trial’s purpose
is to determine if proton therapy can improve overall sur-
vival over IMRT by reducing the risk of severe toxicity to
organs at risk as compared to photon therapy, and new and
more stringent dose constraints were employed [2]. The
compliance criteria of clinical trials are often used as con-
straints for treatment planning and are used for plan scor-
ing upon final review. The method used for designing
compliance criteria should optimally examine a large num-
ber of treatment plans that are considered to be the result
of a significant effort on the part of experienced treatment
planners. In this paper, we assessed the feasibility of the
new and more stringent dosimetric criteria of the RTOG
1308 trial using the IMRT and PSPT plans submitted dur-
ing the design stage of the trial. This study aims at improv-
ing the efficiency of clinical trials launch by establishing
realistic dose constraints in advance.
Methods and materials
Dosimetric compliance criteria for RTOG 1308 trial
The total prescribed dose will be up to 70 Gy (RBE) with-
out exceeding the tolerance dose-volume limits of all crit-
ical normal structures. The compliance criteria used for
two earlier RTOG trials—RTOG 0617 [1] and RTOG 1106
[6]—were used to develop the compliance criteria for the
RTOG 1308 trial. In fact, RTOG 0617 findings indicated
that overall survival was associated with doses to organs at
risk (OARs) [7]. RTOG 1308 dosimetric compliance criteria
were, therefore, designed with a plan to enforce more strin-
gent dose constraints. Additionally, QUANTEC recom-
mendations [8–11] were considered when dose volume
constraints for normal critical structures were developed.
Table 1 lists the RTOG 1308 dosimetric constraints.
Target definitions and treatment planning
The study investigated 26 patients, each of whom had an
IMRT plan and PSPT plan and plans were chosen for
consecutive patients. Clinical proton and photon plans
were generated for each patient either with the intention
of delivering the more optimal plan based on DVH pa-
rameters or as comparison plans for insurance purposes.
The plans were submitted by two institutions, with the
first institution (The University of Pennsylvania) submit-
ting plans for 16 consecutive patients, and the second
institution (MD Anderson Cancer Center) submitting
plans for 10 consecutive patients. The contouring of
normal structures and target volumes as well as motion
management was performed in accordance with guide-
lines from RTOG 1308 at both institutions.
The gross tumor volume (GTV) (for both the primary
tumor and nodal metastases) was contoured based on find-
ings from the computed tomography (CT), positron emis-
sion tomography (PET)/CT scan, and pathology. An iGTV
was created to account for the respiratory motion of the
GTV using an eight-phase four-dimensional (4D) simula-
tion scan by the first institution and a 10-phase 4D CT
simulation scan by the second institution. An internal tar-
get volume (ITV) was then created by expanding the iGTV
by 3–5 mm for sites of nodal metastases and 8 mm for the
primary tumor without extending into uninvolved organs
(such as esophagus, heart, or bone). A planning target vol-
ume (PTV) was created by expanding the ITV isotropically
Table 1 RTOG 1308 dosimetric compliance criteria for target
volumes and normal structures
RT Parameter Per protocol Variation acceptable
% of PTV covered by
prescription dose
95 % ≥95 % of the PTV is
covered by ≥95 %
of the prescription dose
% of ITV (motion-
incorporated CTV)
100 % ≥99 %
Maximum PTV dose
PTV (0.03 cc)
≤120 % RX ≤125 % RX
Minimum PTV dose
(0.03 cc)
≥85 % RX ≥75 % RX
Normal lung
(Both lungs minus GTV)
V5 ≤ 60 % V5 ≤ 65 %
V20≤ 37 % V20 ≤ 40 %
Mean dose < 20 Gy
(RBE)
Mean Dose:
≤ 22 Gy (RBE)
Esophagus Max dose: 74 Gy
(RBE) ≤ 1 cc of partial
circumference
Max dose: 74 Gy
(RBE) ≤ 1.5 cc of
partial circumference
Brachial Plexus V66 ≤ 2.0 cc V66 ≤ 2.5 cc
V70 ≤ 1.0 cc V70 ≤ 1.5 cc
V74 ≤ 0.5 cc V74 ≤ 1.0 cc
V75 ≤ 0.1 cc V75≤ 0.5 cc
Spinal Cord V50 < 0.03 cc V52 < 0.03 cc
Heart V30 ≤ 50 % 50 % ≤ V30 ≤ 55 %
V45 ≤ 35 % 35 % ≤ V45 ≤ 40 %
RX prescription dose
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by 5 mm. The same ITVs and PTVs, as well as the same
contours for normal structures, were used by PSPT and
IMRT plans for each patient. Table 2 lists the mean and
range of volumes in cubic centimeters (cc) for all structures
used in this study. The energy was 6 MV in all IMRT plans.
For proton plans, beam range compensators were devel-
oped to account for range uncertainties, and they provided
proximal and distal margins relative to each PTV. Each
PTV had a unique blocking developed to create a lateral
margin relative. Two to four fields were used for each pro-
ton plan, with beam angles and energies dependent on the
target volume location and size. Most of the 16 patients
had treatment plans (planned by the first institution) that
were coplanar, except for one of the proton plans and three
IMRT plans. The block margin of the proton multileaf col-
limators (MLC) was comparable with beam penumbra. The
first institution used the Varian™ Eclipse treatment planning
system (Varian Medical Systems, Palo Alto, CA) (dose vol-
ume optimizer [11.0.30], anisotropic analytical algorithm
for dose calculation [AAA; 11.0.30] for IMRT plans, and
proton convolution superposition [PCS; 10.0.28] for proton
plans). The second institution used various versions of
Philips Pinnacle (Philips Health Care) to generate photon
plans as well as Variance Eclipse™ (V. 8.9) to generate pro-
ton plans.
Quality assurance of treatment plans using knowledge-
based engineering tool
The prescription dose was 66.6/1.8 Gy for plans that the
first institution submitted and 74 Gy for plans that the
second institution submitted. As such, all plans were
scaled so that a prescription dose of 70/2 Gy RBE covered
95 % of the PTV (as per RTOG 1308 guidelines). The scal-
ing factor for plans that the first institution provided
ranged from between 1.06 and 1.12, and the scaling factor
for plans that the second institution submitted ranged
from between 0.93 and 1.00. The quality of all scaled plans
was evaluated using a knowledge-based engineering (KBE)
tool [12–14]. The tool generates dose volume histogram
for OARs based on the patients’ anatomical information
using predictive models. The predictive models correlates
the anatomical features with the dose features embedded
in the IMRT plans and was trained using a multi-
institutional database of past high-quality plans. The
OARs and their anatomical features were analyzed upon
building the model and a stepwise multivariate regression
was used to assess the significance of the features and es-
tablish the models that correlate anatomy features and
dosimetry features. The details of the model building and
evaluation is described in [13]. The model was later vali-
dated by comparing the DVHs predicted by the model
with the actual DVHs of clinical plans for the following
dosimetric parameters, V5Gy, V10Gy, V20Gy of Lung,
mean dose of heart and esophagus. DICOM data (CT,
RtPlan, RtDose and RtStruc) of all IMRT plans used in
this study were imported to the KBE tool. The tool re-
quires the matching of PTV and OARs names in the can-
didate plan with the names used in the models. The tool
then generates a modeled dose volume histogram (DVH)
for organs at risks for the evaluation plan in study. The
predicted DVHs were compared with the planned DVHs
to assess the quality of plans involved [15].
Data analysis
DVHs for all plans were analyzed using MIM Software,
Inc. [16]. Dose parameters from the two types of plans
were compared using a paired t-test. Differences were
considered significant if p < 0.05 (two-sided).
Results
Quality assurance of photon IMRT plans using
knowledge-based engineering tool
Table 3 lists the various dosimetric parameters of dif-
ferent OARs, as calculated by the KBE tool and treat-
ment planning system. The dosimetric parameters for
all OARs, as calculated by the plans, are either less
than those predicted by the tool or within the confi-
dence limits of the predicted values. This indicates
that the treatment plans used in this study are of
good quality; also, the scaling of plans to the pre-
scription dose of RTOG 1308 did not affect their
quality.
Table 2 Volumes in cubic centimeters (cc) for all structures
(target volume and normal structures) used in this study
Structure Minimum Maximum Median Mean ± SE
Target volume 76.55 1160.83 420.5 548 ± 60
Normal Lung 1328.66 5701.44 2860.8 3033 ± 183
Heart 396.54 1084.13 676.96 671 ± 37
Esophagus 21.59 66.97 33.73 35 ± 2
Spinal Cord 14.25 71.59 37.95 39 ± 3
SE standard error
Table 3 Comparison of OARs dosimetric criteria as estimated by
the treatment planning system and the knowledge based
engineering tool
Dosimetric Criteria Treatment planning
system
Knowledge based
engineering tool
Spinal Cord Maximum
Dose (Gy)
40 ± 2 44 ± 2
Esophagus Maximum
Dose (Gy)
68 ± 3 75 ± 2
Heart V30 Gy (%) 16 ± 4 15 ± 3
Heart V45 Gy (%) 10 ± 3 9 ± 2
Lung V20Gy (%) 27 ± 2 29 ± 2
Lung mean dose (Gy) 17 ± 1 18 ± 2
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Compliance of IMRT and PSPT plans to RTOG 1308
dosimetric criteria
Table 4 lists the percentage deviation unacceptable rates
(i.e., failed to comply with the protocol’s dosimetric cri-
teria) for the different dosimetric criteria of RTOG 1308.
The deviation unacceptable rates for PTV minimum dose
(will be referred to as PTVmin in the rest of the manu-
script) were 23 and 27 % for IMRT and PSPT plans,
respectively. All IMRT plans met the PTV maximum dose
(will be referred to as PTVmax in the rest of the manu-
script) criteria, and only 4 % of PSPT plans failed to meet
these criteria (scored deviation unacceptable). The devi-
ation unacceptable rates in lung V5Gy (%) and V20Gy (%)
compliance criteria were 4 %, and in the mean lung dose
(will be referred to as MLD in the rest of the manuscript),
the rate was 12 % for IMRT plans. All PSPT plans met the
lung V5Gy (%) and V20Gy (%) compliance criteria, and only
4 % failed to meet the MLD criteria (scored deviation un-
acceptable). The deviation unacceptable rates in the heart
V30Gy (%) and V45Gy (%) were 8 and 4 %, respectively, in
IMRT plans; meanwhile, all PSPT plans met the heart
V30Gy (%) and V45Gy (%) compliance criteria. One IMRT
plan failed to meet the spinal cord maximum dose criteria,
but this constraint was met in all PSPT plans.
Photon IMRT and proton PSPT dose volume histogram
analysis
Figure 1 shows the average dose volume histograms for
the target volume, spinal cord, heart, esophagus, and
normal lung in IMRT and PSPT plans (the average dose
volume histogram of each plan type is calculated using
the DVHs of all cases; it represents the arithmetic mean
of the percentage volume at every dose point). Table 5
summarizes the DVH analysis of IMRT and PSPT plans.
A general and observable feature in all PSPT DVHs of
normal structures (Fig. 1) was the steep initial drop in
the percentage volume receiving a certain dose, as com-
pared with IMRT DVHs. The spinal cord percentage
volumes receiving a given dose were around 65 % less in
PSPT than in IMRT plans over almost the entire dose
range. For the heart, the percentage volume receiving a
given dose was about 35 % less in the PSPT plans than
in the IMRT plans up to about 60 Gy. It then became
18 % higher than that of IMRT plans over the rest of the
dose range (from about 60 Gy up to about 80 Gy). The
esophagus percentage volume receiving a given dose was
14 % higher in IMRT plans than in PSPT plans up to
about 15 Gy; it then became 19 % higher in PSPT plans
up to almost 75 Gy. The normal lung percentage vol-
umes receiving a given dose was higher in IMRT plans
than in PSPT plans up to about 20 Gy; they then became
comparable over a dose range from 20 Gy up to about
55 Gy, when it became slightly higher in PSPT plans. It
is observed that the values of lung V5Gy (%), lung V20Gy
(%), MLD, spinal cord maximum dose, heart V5Gy (%),
heart V30Gy (%), heart V45Gy (%), and heart mean dose
were lower in the PSPT plans when compared with
IMRT plans. Lung V5Gy (%) and MLD were significantly
lower (27 % [p < 0.001] and 7.2 % [p < 0.001], respect-
ively) in the PSPT plans. The lung V20Gy (%) was 1.6 %
(p = 0.189) less in PSPT plans. The mean spinal cord
maximum dose was significantly less (27 % [p < 0.001])
in PSPT plans than in IMRT plans. Heart V5Gy (%),
mean heart dose, V30Gy (%), V45Gy (%), and V50Gy (%)
were 59 % (p < 0.001); 48 % (p < 0.001); 41 % (p <0.001);
35 % (p = 0.029); and 27 % less in PSPT plans when
compared with IMRT plans. On the contrary, heart
V60Gy (%), V66Gy (%), and V70Gy (%) were, respectively, 8;
13, and 18 % higher in PSPT plans as compared with
IMRT plans. The mean values for the esophagus mean
and maximum doses were very close (1–2.5 %) in both
the IMRT and PSPT plans. The inferior performance of
high dose in heart, lung and esophagus in PSPT is due
to the limitation of PSPT in changing field portal at dif-
ferent proton energies [17].
Discussion
Quality assurance of treatment plans using knowledge-
based engineering tool
The knowledge-based engineering tool is a quick and re-
liable tool for checking the quality of treatment plans.
This tool [12] was trained using a multi-institutional
dataset of high-quality plans to take into consideration
Table 4 Deviation unacceptable rates (expressed as percentage)
for the different dosimetric criteria
Structure Dosimetric
Parameter
Photon IMRT Proton PSPT
% of cases
failed to meet
the criteria
% of cases failed
to meet the
criteria
PTV % of PTV
covered
by RX
0 0
PTV minimum 23 28
PTV maximum 0 4
Spinal Cord Maximum
dose
4 0
Total Lung (both
lungs – GTV)
V5 4 0
V20 4 0
Mean dose 12 4
Heart V30 8 0
V45 4 0
Brachial Plexus V70 10 5
V74 10 0
V75 5 0
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the variations in the anatomies of patients, institutional
protocols, and treatment techniques. Treatment plans
are considered to be of good quality if their calculated
dosimetric parameters are less than the values predicted
by the tool or if they lie within the confidence level (un-
certainty level) of the predicted ones. The quality of all
IMRT plans was assessed using this tool. As indicated in
Table 4, the values of various dosimetric parameters
(volumes receiving a certain dose; mean dose and max-
imum dose of various structures) as calculated by the
treatment plans were within the uncertainty of the
values predicted by the tool, indicating that the quality
of all plans are generally acceptable. This is a very im-
portant step for ensuring that the plans used for estab-
lishing the dosimetric criteria are not only acceptable
but also of good quality, and it also indicates that the
scaling of the plans to the prescription dose of RTOG
1308 did not affect their quality.
Compliance of IMRT and PSPT plans to RTOG 1308
dosimetric criteria
This study was conducted when designing the new and
more strict dose constraints now in place for the RTOG
1308 clinical trial to test if these criteria are achievable;
based on its findings, many criterion were relaxed (for
example, the minimum dose of PTV) or removed (for
example, the maximum heart dose of 74 Gy; this was re-
moved after protocol enrollment already started based
on the current study findings). Such a study represents a
practical improvement in the trial planning processes.
By establishing in advance that dosimetric compliance
criteria are achievable across a variety of centers and
techniques. RTOG and now NRG Oncology clinical tri-
als usually specify two levels of constraints: per protocol
and variation acceptable. Ideally, all plans are expected
to meet the per-protocol constraints; however, plans are
still considered acceptable if there is a minor deviation
from the per-protocol constraints and it is still within
the range of the variation-acceptable constraints. As a
general rule, if the deviation unacceptable rates signifi-
cantly exceed 10 %, the criterion has to be revised. The
deviation unacceptable rates for all RTOG 1308 criteria
were less than 10 %, with the exception of the PTVmin
dose and mean lung dose (MLD). We compared the
PTVmin of the plans with that required by the protocol
(Table 2) and noticed that the deviations of the plans
from the protocol were less than 5 % in four IMRT plans
and ranged between 20 and 34 % in the other two cases.
In the PSPT plans, the deviation ranged from between
2.9 and 4.7 % in two cases, ranged from between 8 and
Fig. 1 Average dose volume histograms of IMRT and PSPT plans. a Target Volume. b Spinal Cord. c Esophagus. d Heart. e Normal Lung
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12 % in four cases, and reached 20 % in one case. This
effect is likely due to lack of a PTVmin institutional con-
straint at the time the plans were developed. The devia-
tions of the IMRT plans that failed the MLD criterion
from the protocol dose constraints ranged from between
11 and 20 %. Only one PSPT plan failed to meet the
MLD criterion, and the deviation of the plan was 15 %
from the protocol dose constraints. Such deviation un-
acceptable rates in some of the plans were dealt with
using the protocol allowable variations (prescribing 95 %
of the prescription dose to 95 % of PTV or using a pre-
scription dose of 60 Gy instead of 70 Gy) [2].
Photon IMRT and proton PSPT dose volume histogram
analysis
The trend of our results agreed qualitatively with those
reported by Berman et al.[18] for lung V5Gy (%), mean
lung dose, spinal cord maximum dose, and esophagus
mean dose. However, a disagreement was observed be-
tween our results and Berman et al.[18] on the mean
heart dose and the lung V20Gy (%): They reported 4.6 %
higher mean heart dose in PSPT plans as compared with
IMRT plans, whilst in our study, the mean heart dose
was 48 % less in PSPT plans as compared with IMRT
plans. The lung V20Gy (%) was 2.7 % higher in PSPT
plans compared with in IMRT plans in Berman et al.’s
[18], while it was 1.6 % higher in IMRT plans as com-
pared with PSPT plans in our investigation. Chang et al.
[19] compared photon and proton plans for stage III
NSCLC patients and reported a reduction of 9–3 Gy
(compared with 12 Gy in our investigation) in the spinal
cord maximum dose and 3 Gy (compared with 1.31 Gy
in our study) in the mean lung dose when proton beams
were used as compared with IMRT. They also reported
15-17 % (12 % in our study) and 4 % (~0.5 % in our
study) in lung V5Gy (%) and lung V20Gy (%), respectively.
The prescription dose was different in Chang et al.’s [19]
study; they used two different dose levels: 60–63 Gy
(RBE) and 74 Gy (RBE) for protons and photons, re-
spectively. Kesarwala et al. [20] examined the feasibility
of intensity-modulated proton therapy (IMPT) for elect-
ive nodal irradiation in locally-advanced none small-cell
lung cancer. They reported a mean lung dose of 17.2 ±
0.9 (Gy/CGE) (compared to 17.8 ± 0.9 Gy in our IMRT
results) using photon IFRT and 11 ± 0.8 Gy/CGE (com-
pared to 16.4 ± 0.9 Gy in our PSPT results) using IMPT;
our results on IMRT are comparable to their results.
They also reported lung V20Gy of 27.9 ± 1.6 % (compared
to 28.1 ± 1.6 % in our IMRT plans) and 22.9 ± 1.5 %
(compared to 27.6 ± 1.5 % in our PSPT plans). Our
Table 5 Analysis of dose volume histograms of IMRT and PSPT plans
Structure Photon IMRT Proton PSPT
Median Mean ± SE Median Mean ± SE
PTV % of PTV covered by RX 95 95 95 95
PTV minimum 57.0 56.7 ± 1.5 55.0 55.5 ± 1.4
PTV maximum 81.3 81.6. ± 0.7 79.9 80.9 ± 0.9
Normal lung
(total lungs – GTV)
Lung V5 42.6 47.2 ± 2.6 35.3 34.4. ± 1.6
Lung V20 27.9 28.1 ± 1.6 29.32 27.6 ± 1.5
Mean Lung dose 18.4 17.8 ± 0.9. 18.3 16.4. ± 0.9.
Spinal cord Spinal Cord maximum dose 43.8 43.5 ± 1.4 37.9 31.7 ± 3.1
Heart V5 39.4 47 ± 6 16.6 19. ± 3
V30 15.7 19 ± 4 9.7 11 ± 2
V45 7.7 12.1 ± 2.7 7.4 7.8 ± 1.5
V50 5.4 9.8. ± 2.3 6.5. 7.1 ± 1.4
V60 2.6 6.2 ± 1.5 4.2 6.7 ± 1.2
V66 1.8 4.2 ± 1 2.9 4.7 ± 1.1
Heart mean dose 12.7 14.9 ± 2.4 6.7 7.7. ±1.4
Maximum Dose 78 69.3. ± 4.5 76.4 68.5. ± 4.4.
Esophagus Mean dose 20.1 22.7 ± 1.9 21.2 23 ± 2
Maximum dose 76.2 73.2 ± 2.5 74.1 71. ± 3
Brachial Plexus V70 0 0.50 0 1.0
V74 0 0.27 0 0.10
V75 0 0.18 0 0.11
SE standard error
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IMRT plans results are in good agreement with their re-
sults. However, there are some differences in the proton
plans, as they used IMPT, which resulted in lower mean
lung dose and lung V20Gy.
Conclusion
Most of the dosimetric criteria were achieved using the
IMRT and PSPT plans, suggesting that the RTOG 1308
dosimetric compliance criteria are feasible and achiev-
able despite the relatively high deviation unacceptable
rate in the PTVmin dose compliance. The KBE QA tool
indicated that the plans used in this study are of good
quality. PSPT plans led to a significantly lower heart
V5Gy (%), V30Gy (%), V45Gy (%), V50Gy (%), heart mean
dose, lung V5Gy (%), spinal cord maximum dose, and
esophagus maximum dose as compared with IMRT
plans. PSPT led to a numerically slightly higher heart
V60Gy (%), V66Gy (%), brachial plexus V70Gy (CC), and
esophagus mean dose; however, these differences were
within statistical uncertainty.
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